Docoh
Loading...
Sign up Log in

LGND Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Company profile

Ticker
LGND
Exchange
NASDAQ
Website
www.ligand.com/
CEO
John Higgins
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...
Former names
LIGAND PHARMACEUTICALS
SEC CIK
0000886163
Corporate docs
IRS number
770160744

LGND stock data

(
)

News

Pro users get this 30m faster
Here Are The Stocks With The Highest Short Interest Rate
25 Feb 21
Short interest rates can be used to predict the potential direction of an individual stock.
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
11 Feb 21
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11)
Stocks That Hit 52-Week Highs On Wednesday
10 Feb 21
This morning 533 companies reached new 52-week highs.
Top 30 High Short Interest Stocks As Of Wednesday, Feb. 10, 2021 (Via HighShortInterest.com)
10 Feb 21
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs
10 Feb 21

Press releases

Pro users get this 30m faster
Final Results for the year ended 31 December 2020
1 Apr 21
Leeds, UK, April 01, 2021 (GLOBE NEWSWIRE) -- 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS) ("4D", the "Company" or, together with its subsidiaries, the "Group"), a pharmaceutical company leading the development of Live
4D Pharma Appointments Paul Maier to the Board as Non-Executive Director
1 Mar 21
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of Paul Maier as
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
3 Feb 21
Raises 2021 Financial Guidance Conference Call Begins at 8:30 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and 12 months ended December 31,
Ligand Pharmaceuticals, Inc. to Host Earnings Call
3 Feb 21
Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
2 Feb 21

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

23 Feb 21
11 Apr 21
31 Dec 21

Financial summary

Financial statements Chart LGND financial data
Quarter (USD)
 Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 47.96M 47.96M 47.96M 47.96M 47.96M 47.96M
Cash burn (monthly) 136.38M 2.03M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 460.19M 6.84M n/a n/a n/a n/a
Cash remaining -412.23M 41.13M n/a n/a n/a n/a
Runway (months of cash) -3.0 20.3 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Recent insider trades

LGND insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
22 Feb 21 Kozarich John W Common Stock Option exercise Aquire M No No 10.12 2,500 25.3K 29,708
22 Feb 21 Kozarich John W NQSO Common Stock Option exercise Dispose M No No 10.12 2,500 25.3K 4,835
15 Feb 21 Korenberg Matthew E Common Stock Payment of exercise Dispose F No No 172.46 969 167.11K 39,443
15 Feb 21 Korenberg Matthew E Common Stock Payment of exercise Dispose F No No 172.46 906 156.25K 40,412
15 Feb 21 Korenberg Matthew E Common Stock Payment of exercise Dispose F No No 172.46 434 74.85K 41,318
15 Feb 21 Higgins John L Common Stock Payment of exercise Dispose F No No 172.46 2,061 355.44K 337,848
15 Feb 21 Higgins John L Common Stock Payment of exercise Dispose F No No 172.46 1,947 335.78K 339,909
15 Feb 21 Higgins John L Common Stock Payment of exercise Dispose F No No 172.46 1,204 207.64K 341,856
15 Feb 21 Berkman Charles S Common Stock Payment of exercise Dispose F No No 172.46 442 76.23K 27,891
15 Feb 21 Berkman Charles S Common Stock Payment of exercise Dispose F No No 172.46 368 63.47K 28,333
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

LGND institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
 Current Prev Q Change
Total holders 233 248 -6.0%
Opened positions 29 31 -6.5%
Closed positions 44 42 +4.8%
Increased positions 80 89 -10.1%
Reduced positions 89 94 -5.3%
13F shares
 Current Prev Q Change
Total value 2.29B 2.37B -3.3%
Total shares 22.7M 22.69M +0.0%
Total puts 793.5K 1.2M -33.6%
Total calls 281.6K 113.72K +147.6%
Total put/call ratio 2.8 10.5 -73.2%
Largest owners
 Shares Value Change
William Blair Investment Management 2.04M $202.98M +7.7%
BLK Blackrock 1.97M $195.52M -8.0%
JHG Janus Henderson 1.61M $160.35M +0.4%
Vanguard 1.46M $145.09M +2.1%
Wasatch Advisors 1.17M $116.26M +4.9%
STT State Street 1.17M $115.9M +19.9%
Cardinal Capital Management 1.09M $108.23M +15.6%
MCQEF Macquarie 894.68K $88.98M +18.3%
Conestoga Capital Advisors 716.44K $71.25M +1.0%
Villere ST Denis J & Co 642.07K $63.85M -3.2%
Largest transactions
 Shares Bought/sold Change
Victory Capital Management 5.91K -251.78K -97.7%
STT State Street 1.17M +193.76K +19.9%
SLFPF Standard Life Aberdeen 369.08K +172.09K +87.4%
BLK Blackrock 1.97M -170.11K -8.0%
GS Goldman Sachs 268.69K +165.15K +159.5%
Chicago Capital 332.85K -152.99K -31.5%
Cardinal Capital Management 1.09M +146.97K +15.6%
William Blair Investment Management 2.04M +145.67K +7.7%
MCQEF Macquarie 894.68K +138.55K +18.3%
Norges Bank 134.7K +134.7K NEW
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Cytokinetics • AbCellera Biologics
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: AbCellera, abemaciclib, Accent, acid, Adalvo, Adept, affinity, AI, alfa, alia, allegedly, alliance, altogether, Alvogen, amide, AML, annex, appoint, appointed, Arabia, ASCEND, Asia, Asian, asparaginase, bacterium, batoclimab, Bayer, behavior, Beloteca, benchmark, BI, binding, bintrafusp, bioactivity, BLA, Bonsity, Bonteo, Brian, Buyer, Caldera, career, Carolina, carrier, CDK, CF, CFTR, chicken, choice, chose, chosen, Cipla, CNS, commonly, conjugate, conjugated, consortium, constitute, constituted, contact, correlate, cow, customizable, deep, delinquency, denied, denying, deprioritizing, diphtheria, discern, discrimination, discriminatory, distancing, Distinguished, doctrine, Dr, DUPLEX, durability, Durham, duty, earnout, EC, ELAINE, emerge, epidemic, EQRx, Erwinia, escalation, Eton, evolve, expert, feedback, fiduciary, fight, fisogatinib, flat, FORTEO, forum, founder, FPRE, fraudulently, Gavi, GE, GEM, gene, Genekey, globe, grow, growing, harassment, heat, Higuchi, HitGen, hospital, hospitalization, hotline, hydrolase, IgG, imposed, inapplicable, incentivizing, induced, Inst, Intelligence, interval, intramuscular, invasive, IP, irbesartan, Jazz, joint, Kangchen, kind, lab, leader, licensure, lifespan, linked, Livogiva, longest, loyalty, LTPTM, luminespib, Lundstrom, lymphoblastic, magnitude, Mainland, Malaysia, markedly, marker, MDS, MENA, meningococcal, micro, microbial, microcapillary, Minotaur, missed, molecular, morbidity, mutant, mutation, NaN, Neuritek, neurodegenerative, neurological, nonclinical, nonsense, nontransferable, NSCLC, obstructive, OmniTaur, OnKure, optica, ORR, output, outsourced, pain, paired, pandemic, Pandion, Pat, pathway, pause, peak, pegaspargase, Pelican, percent, Pfenex, pharmacodynamic, Phoenix, pMDI, pneumococcal, Pneumosil, posed, pre, premature, Prequalification, prevalent, Professor, prophylactic, protocol, proud, PTAB, pulmonary, rat, readthrough, recommended, redirecting, refusal, regorafenib, remission, reopening, retention, retirement, RHHBY, Roche, role, ROW, RTOR, RubrYc, salary, Saudi, SC, scalable, SCS, secondary, sensitive, sequencing, Serum, sexual, shock, SII, silico, Singapore, slightly, Smider, solubilize, spread, stack, staffing, Stanford, Stella, strive, subsidized, substance, sugemalimab, suggest, suitable, superior, suppression, Taiho, teclistamab, teriparatide, territory, Thailand, thereunder, thousand, toxin, tradename, transformative, transmembrane, travel, Travere, truncated, tuition, unresectable, unvested, usage, vaccine, Valentino, VALOR, Vaughn, Veklury, versatility, vivo, VOYAGE, waived, welfare, Wistar, withheld, xPloration, XRPro, zimberelimab
Removed: accumulation, ADHF, antibiotic, assured, averaged, avian, bioavailability, BMS, calculating, Capitsol, clarified, classification, combining, death, delafloxacin, Department, DUET, expiring, faster, fluoroquinolone, improving, inflammation, instrument, interpretation, interpretative, invoice, Journal, lived, maximize, MRSA, nondeductible, notably, principle, repertoire, revision, space, survival, uncollectible, Washington, week, wholly, wrong
From filing 10-K 2020 FY

Financial reports

View all
10-K
2020 FY
Annual report
23 Feb 21
10-Q
2020 Q3
Quarterly report
6 Nov 20
10-Q
2020 Q2
Quarterly report
7 Aug 20
10-Q
2020 Q1
Quarterly report
8 May 20
10-K
2019 FY
Annual report
27 Feb 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18

Current reports

View all
8-K
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
3 Feb 21
8-K
Entry into a Material Definitive Agreement
28 Jan 21
8-K
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
21 Dec 20
8-K
Departure of Directors or Certain Officers
16 Dec 20
8-K/A
Financial Statements and Exhibits
10 Dec 20
8-K
Other Events
2 Dec 20
8-K
Other Events
23 Nov 20
8-K
Amendments to Articles of Incorporation or Bylaws
30 Oct 20
8-K
Ligand Reports Third Quarter 2020 Financial Results
30 Oct 20
8-K
Results of Operations and Financial Condition
20 Oct 20

Registration and prospectus

View all
S-8
Registration of securities for employees
27 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
30 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
16 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
11 Sep 20
SC TO-T
Third party tender offer statement
31 Aug 20
SC TO-C
Information about tender offer
10 Aug 20
SC TO-C
Information about tender offer
10 Aug 20
S-8
Registration of securities for employees
8 Aug 19
S-8
Registration of securities for employees
28 Jul 16
D
$85.44M in equity, sold $85.44M, 22 investors
24 Jan 16

Proxies

View all
DEF 14A
Definitive proxy
12 Nov 20
PRE 14A
Preliminary proxy
30 Oct 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEF 14A
Definitive proxy
24 Apr 20
DEFA14A
Additional proxy soliciting materials
4 Jun 19
DEF 14A
Definitive proxy
23 Apr 19
DEFA14A
Additional proxy soliciting materials
23 Apr 19
DEFA14A
Additional proxy soliciting materials
3 Jun 18
PRER14A
Preliminary revised proxy
22 May 18
DEFA14A
Additional proxy soliciting materials
30 Apr 18

Other

View all
UPLOAD
Letter from SEC
12 Jan 21
CORRESP
Correspondence with SEC
5 Jan 21
UPLOAD
Letter from SEC
22 Dec 20
CORRESP
Correspondence with SEC
15 Sep 20
CT ORDER
Confidential treatment order
15 Jun 20
CT ORDER
Confidential treatment order
23 Aug 18
CT ORDER
Confidential treatment order
22 May 18
CT ORDER
Confidential treatment order
2 Apr 18
UPLOAD
Letter from SEC
6 Feb 18
CORRESP
Correspondence with SEC
16 Jan 18

Ownership

View all
4
LIGAND PHARMACEUTICALS / JOHN W KOZARICH ownership change
23 Feb 21
4
LIGAND PHARMACEUTICALS / Charles S Berkman ownership change
18 Feb 21
4
LIGAND PHARMACEUTICALS / MATTHEW W FOEHR ownership change
18 Feb 21
4
LIGAND PHARMACEUTICALS / JOHN L HIGGINS ownership change
18 Feb 21
4
LIGAND PHARMACEUTICALS / Matthew E Korenberg ownership change
18 Feb 21
SC 13G/A
LIGAND PHARMACEUTICALS / CARDINAL CAPITAL MANAGEMENT ownership change
16 Feb 21
SC 13G
LIGAND PHARMACEUTICALS / STATE STREET ownership change
16 Feb 21
4
LIGAND PHARMACEUTICALS / Todd C Davis ownership change
12 Feb 21
SC 13G
LIGAND PHARMACEUTICALS / MACQUARIE ownership change
12 Feb 21
SC 13G/A
LIGAND PHARMACEUTICALS / JANUS HENDERSON ownership change
11 Feb 21

Patents

View all
GRANT
Utility
Method for analysis using X-ray fluorescence
16 Mar 21
The present invention is a method to quantify biomarkers.
APP
Utility
Methods and Compositions Associated with the Granulocyte Colony-stimulating Factor Receptor
18 Feb 21
Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR).
APP
Utility
Imidazo-fused Heterocycles and Uses Thereof
11 Feb 21
Compounds and methods in the fields of chemistry and medicine are disclosed.
GRANT
Utility
1H-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors
12 Jan 21
Inventors: Stephen Stokes, Christopher John Graham, Stuart Christopher Ray, Emma Jayne Stefaniak
GRANT
Utility
Methods and compositions for modulating hormone levels
28 Dec 20
Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions.

Transcripts

View all
2020 Q4
Earnings call transcript
3 Feb 21
2020 Q3
Earnings call transcript
30 Oct 20
2020 Q2
Earnings call transcript
3 Aug 20
2020 Q1
Earnings call transcript
6 May 20
2019 Q3
Earnings call transcript
5 Nov 19
2019 Q2
Earnings call transcript
30 Jul 19
2019 Q1
Earnings call transcript
2 May 19
2018 Q4
Earnings call transcript
8 Feb 19
2018 Q3
Earnings call transcript
8 Nov 18
2018 Q2
Earnings call transcript
6 Aug 18

Reddit threads

View all